ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
123.800,96
-0,05%
S&P 500
5.587,62
-0,21%
US Dollar vs BRL
5,8269
0,48%
Bitcoin
82.704,08
-1,20%
Brent Oil
70,145
-0,77%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Lexeo Therapeutics Inc (LXEO)

  7. Lexeo Therapeutics Inc (LXEO) Notícias

LXEO

Lexeo Therapeutics (LXEO)

Lexeo Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LXEO
DataHoraFonteTítuloCódigoCompanhia
21/02/202519:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
19/02/202518:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
12/02/202511:35Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LXEOLexeo Therapeutics Inc
04/02/202517:45Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:LXEOLexeo Therapeutics Inc
13/01/202509:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXEOLexeo Therapeutics Inc
07/01/202509:30GlobeNewswire Inc.Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LXEOLexeo Therapeutics Inc
27/12/202416:59Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LXEOLexeo Therapeutics Inc
20/12/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LXEOLexeo Therapeutics Inc
19/12/202409:00GlobeNewswire Inc.Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial OfficerNASDAQ:LXEOLexeo Therapeutics Inc
13/12/202410:19Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LXEOLexeo Therapeutics Inc
02/12/202419:04Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:LXEOLexeo Therapeutics Inc
13/11/202409:35Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LXEOLexeo Therapeutics Inc
13/11/202409:33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LXEOLexeo Therapeutics Inc
13/11/202409:30GlobeNewswire Inc.Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial ResultsNASDAQ:LXEOLexeo Therapeutics Inc
30/10/202407:14GlobeNewswire Inc.Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceNASDAQ:LXEOLexeo Therapeutics Inc
22/10/202408:30GlobeNewswire Inc.Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 ConferenceNASDAQ:LXEOLexeo Therapeutics Inc
05/09/202408:30GlobeNewswire Inc.Lexeo Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LXEOLexeo Therapeutics Inc
12/08/202408:00GlobeNewswire Inc.Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
15/07/202407:00GlobeNewswire Inc.Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
11/07/202409:00GlobeNewswire Inc.Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024NASDAQ:LXEOLexeo Therapeutics Inc
08/07/202408:00GlobeNewswire Inc.Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of DirectorsNASDAQ:LXEOLexeo Therapeutics Inc
09/05/202408:00GlobeNewswire Inc.Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
22/04/202408:30GlobeNewswire Inc.Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
16/04/202408:30GlobeNewswire Inc.Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia CardiomyopathyNASDAQ:LXEOLexeo Therapeutics Inc
13/03/202417:22GlobeNewswire Inc.Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity FinancingNASDAQ:LXEOLexeo Therapeutics Inc
11/03/202417:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LXEOLexeo Therapeutics Inc
11/03/202410:29Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LXEOLexeo Therapeutics Inc
11/03/202408:42GlobeNewswire Inc.Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:LXEOLexeo Therapeutics Inc
11/03/202408:30GlobeNewswire Inc.Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity FinancingNASDAQ:LXEOLexeo Therapeutics Inc
05/02/202409:00GlobeNewswire Inc.Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive AppointmentsNASDAQ:LXEOLexeo Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:LXEO

Seu Histórico Recente

BOV
BHIA3
Grupo Casas Bahia ON
BOV
COGN3
COGNA ON
BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
ADMF3
Reag ON
BOV
LVTC3
Livetech Da Bahia Indust... ON
BOV
DMVF3
D1000 Varejo Farma Parti... ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
PMAM3
PARANAPANEMA ON
BOV
HBOR3
HELBOR ON
BOV
OIBR3
OI ON
BOV
PCAR3
PÃO DE AÇUCAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios